These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 6858934)
1. Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenol. Reiter MJ; Hammill SC; Shand DG; Verghese C; McCarthy E; Pritchett EL Am J Cardiol; 1983 Jul; 52(1):83-7. PubMed ID: 6858934 [TBL] [Abstract][Full Text] [Related]
2. Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics. Hammill SC; Shand DG; Routledge PA; Hindman MC; Baker JT; Pritchett EL Circulation; 1982 Feb; 65(2):369-75. PubMed ID: 7053896 [TBL] [Abstract][Full Text] [Related]
3. The relation of the kinetics of pirmenol to its antiarrhythmic efficacy. Johnson BF; Haffajee CI; Woodman T; Sloan KL J Clin Pharmacol; 1988 May; 28(5):401-5. PubMed ID: 3392237 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and pharmacokinetics of oral pirmenol, a new antiarrhythmic drug. Garg DC; Jallad NS; Singh S; Ng KF; Weidler DJ J Clin Pharmacol; 1988 Sep; 28(9):812-7. PubMed ID: 2466056 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravenous pirmenol hydrochloride for treatment of ventricular arrhythmias: a controlled comparison with lidocaine. Anderson JL; Lutz JR; Sanders SW; Nappi JM J Cardiovasc Pharmacol; 1983; 5(2):213-20. PubMed ID: 6188892 [No Abstract] [Full Text] [Related]
6. Hemodynamic effects of pirmenol, a new antiarrhythmic agent, assessed noninvasively. Toivonen LK; Nieminen MS Int J Cardiol; 1986 Feb; 10(2):111-8. PubMed ID: 3943931 [TBL] [Abstract][Full Text] [Related]
7. Acute haemodynamic effects of the antiarrhythmic agent pirmenol in cardiac patients: a comparison with lidocaine. Nieminen MS; Toivonen LK; Manninen V; Frick MH Eur Heart J; 1986 Feb; 7(2):150-7. PubMed ID: 3516703 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and efficacy of pirmenol hydrochloride in the treatment of ventricular dysrhythmia. Lee TG; Goldberg AD; Chang T; Serkland MT; Yakatan GJ; Johnson EL; Toole JG; Goldstein S J Cardiovasc Pharmacol; 1983; 5(4):632-7. PubMed ID: 6193362 [TBL] [Abstract][Full Text] [Related]
9. Conversion of paroxysmal atrial fibrillation to sinus rhythm by intravenous pirmenol. A placebo controlled study. Toivonen LK; Nieminen MS; Manninen V; Frick MH Br Heart J; 1986 Feb; 55(2):176-80. PubMed ID: 3510642 [TBL] [Abstract][Full Text] [Related]
10. Pirmenol: an antiarrhythmic drug with unique electrocardiographic features--a double-blind placebo-controlled comparison with quinidine. Salerno DM; Fifield J; Farmer C; Hodges M Clin Cardiol; 1991 Jan; 14(1):25-32. PubMed ID: 2019027 [TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic efficacy of pirmenol in the treatment of premature ventricular complexes. Toivonen LK; Nieminen MS; Manninen V; Frick MH Eur Heart J; 1985 Sep; 6(9):737-44. PubMed ID: 2416566 [TBL] [Abstract][Full Text] [Related]
12. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia. Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of oral pirmenol. Ellenbogen KA; Roark SF; Sintetos AL; Smith MS; McCarthy EA; Smith WM; Kates RE; Pritchett EL Clin Pharmacol Ther; 1987 Oct; 42(4):405-10. PubMed ID: 3665339 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Kjekshus J; Bathen J; Orning OM; Storstein L Am J Cardiol; 1984 Feb; 53(5):72B-78B. PubMed ID: 6421140 [TBL] [Abstract][Full Text] [Related]
15. Hemodynamic effects of pirmenol and lidocaine: a placebo-controlled, double-blind, comparative study. Nieminen MS; Toivonen L; Manninen V; Frick H Am J Cardiol; 1987 Jun; 59(16):27H-32H. PubMed ID: 3296728 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations. de Buitleir M; Crevey BJ; Johnson T; Kou WH; Nelson SD; Schmaltz S; Morady F Am Heart J; 1988 Aug; 116(2 Pt 1):379-84. PubMed ID: 2456681 [TBL] [Abstract][Full Text] [Related]
17. Preliminary study of pirmenol in the treatment of ventricular arrhythmias. Gimeno Gascon JV; Algarra Vidal FJ Am J Cardiol; 1987 Jun; 59(16):53H. PubMed ID: 3591713 [TBL] [Abstract][Full Text] [Related]
18. Initial and long-term outpatient experience with pirmenol for control of ventricular arrhythmias. Hampton EM; Anderson JL; Lutz JR; Nappi JM Eur J Clin Pharmacol; 1986; 31(1):15-22. PubMed ID: 3780822 [TBL] [Abstract][Full Text] [Related]
19. Electrophysiology and antiarrhythmic efficacy of intravenous pirmenol in patients with sustained ventricular tachyarrhythmias. Liem LB; Clay DA; Franz MR; Swerdlow CD Am Heart J; 1987 Jun; 113(6):1390-6. PubMed ID: 3591608 [TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease. Easley AR; Mann DE; Reiter MJ; Sakun V; Sullivan SM; Magro SA; Luck JC; Wyndham CR Am J Cardiol; 1986 Jul; 58(1):86-9. PubMed ID: 3728337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]